

This correspondence is being deposited with the United States Postal Service as Express Mail No. EV 332107545 in an envelope addressed to:

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

PATENT  
Attorney Docket No.: 014058-013534US  
Client Ref. No.: 494 C4  
Customer No.: 20350

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

*GAIGER et al.*

Application No.: Not yet assigned

Filed: Herewith

For: COMPOSITIONS AND METHODS  
FOR THE DETECTION, DIAGNOSIS  
AND THERAPY OF  
HEMATOLOGICAL MALIGNANCIES

Examiner: Not yet assigned

Art Unit: Not yet assigned

**PRELIMINARY AMENDMENT**

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In order to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, Applicants submit that the computer-readable form in the instant application is identical with the Sequence Listing for Application No. 10/040,862, filed November 6, 2001. In accordance with 37 C.F.R. § 1.821(e), please use the last-filed computer-readable form filed in Application No. 10/040,862 as the computer-readable form for the instant application. Duplicate paper copies of the Sequence Listing from Application No. 10/040,862 on compact disc are submitted herewith. The information in the paper copy on compact disc of the Sequence Listing is identical to that

Appl. No. Not yet assigned  
Amdt. dated January 23, 2004  
Preliminary Amendment

PATENT

which is in the computer readable form submitted June 25, 2002, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

**Amendments to the Specification** begin on page 3 of this paper.

**Remarks** begin on page 4 of this paper.